ライフサイエンスコーパス: papillomavirus

1 of innate immune signaling in the control of papillomavirus.

2 ins in 3D with a case study focused on human papillomavirus.

3 aves differently between the two families of papillomaviruses.

4 ses BK/JC/MCV, human adenoviruses, and human papillomaviruses.

5 with which to study sexually transmission of papillomaviruses.

6 lving a conserved tyrosine (Y) in the bovine papillomavirus 1 (BPV-1) E2 protein at amino acid 102.

7 ospho-acceptor site on the HPV-16 and bovine papillomavirus 1 (BPV-1) L2 proteins.

8 Here we have discovered that the bovine papillomavirus 1 (BPV-1) transcription and replication r

9 d a skin cancer model, in which Mus musculus papillomavirus 1 (MmuPV1) infection caused cSCCs in cycl

10 ery of a murine papillomavirus, Mus musculus papillomavirus 1 (MmuPV1), and how its experimental use

11 detect viral nucleic acids, including human papillomavirus 16 (HPV-16) and parvovirus B19 (PB-19), w

12 ildtype p53 (p53WT) inactivated by the human papillomavirus 16 (HPV16) E6 oncogene.

13 Human papillomavirus 16 (HPV16) E7 has long been known to stab

14 Infectious human papillomavirus 16 (HPV16) L1/L2 pseudovirions were found

15 t, dramatically decreased infection of human papillomavirus 16 (HPV16) pseudovirus (PsV).

16 m a much higher incidence of high-risk human papillomavirus 16 (HPV16)-mediated carcinogenesis of the

17 of E2 host gene regulation.IMPORTANCE Human papillomavirus 16 (HPV16)-positive tumors that retain ex

18 sion.IMPORTANCE Although the high-risk human papillomavirus 16 infects anogenital and oropharyngeal s

19 1 month after the last dose of 2-dose human papillomavirus 16/18 AS04-adjuvanted (AS04-HPV-16/18) va

20 Human papillomaviruses 16 (HPV16) is the primary causative age

21 Human papillomavirus-16 and HPV-18 incidence were similar (~10

22 Human papillomavirus-16 cleared significantly slower than HPV-

23 Human papillomavirus-16 incidence was higher among high-grade

24 g a convolutional neural network (ii) equine papillomavirus 2 (EcPV2) infection, detected using PCR a

25 ralia, high uptake of the quadrivalent human papillomavirus (4vHPV) vaccine has led to reductions in

26 Human papillomavirus 58 (HPV58) is found in 10 to 18% of cervi

27 t to the replication origin.IMPORTANCE Human papillomaviruses affect an estimated 75% of the sexually

28 f tumor-bearing mice with R-DOTAP plus human papillomavirus Ags induces complete regression of large

29 al data on the E6/E7 mRNA-based Aptima human papillomavirus (AHPV) assay exceeding three years in com

30 er genital tract infection with MmuPV1 mouse papillomavirus and display focal histopathological abnor

31 arcinoma (SCC) is associated with both human papillomavirus and HIV infection.

32 t DNA viruses (anelloviruses, herpesviruses, papillomaviruses and polyomaviruses) over time were obse

33 es that use this tethering mechanism include papillomaviruses and the gammaherpesviruses Epstein-Barr

34 l insight into the complex interplay between papillomaviruses and their hosts.

35 h known p16 tumor status (surrogate of human papillomavirus) and cigarette smoking history (pack-year

36 upport a working model of innate immunity to papillomaviruses, and the model provides a framework for

37 Our data reveal a virome dominated by papillomaviruses, anelloviruses, herpesviruses, and parv

38 Papillomaviruses are small, double-stranded DNA viruses

39 TEFb binding domain of Brd4.IMPORTANCE Human papillomaviruses are the major causative agents of cervi

40 e recognition of tobacco, alcohol, and human papillomavirus as etiological agents in oral and head an

41 herapy (RT) for selected patients with human papillomavirus-associated oropharyngeal squamous cell ca

42 splatin are favorable in patients with human papillomavirus-associated oropharyngeal squamous cell ca

43 n and frequency of infection declined, human papillomavirus-associated oropharyngeal squamous-cell ca

44 In the human papillomavirus-associated TC-1 model, vaccination with t

45 in-which has been associated with beta human papillomavirus (beta-HPV) infection-is increased by more

46 Beta genus human papillomaviruses (beta-HPVs) cause cutaneous squamous ce

47 ted the association between beta genus human papillomaviruses (betaPV) and keratinocyte carcinoma in

48 Tyrosine 102 is conserved between delta papillomavirus BPV-1 and alpha papillomavirus HPV-31 E2.

49 C57BL/6J mice are susceptible to a transient papillomavirus cervicovaginal infection, and mice defici

50 ngs from previous studies of cutaneous human papillomavirus (cuHPV) infection and keratinocyte carcin

51 Plasma circulating tumor human papillomavirus DNA (ctHPVDNA) is a sensitive and specifi

52 Tobacco- or human papillomavirus- driven oropharyngeal squamous cell carci

53 ChlR1 is required for loading of the bovine papillomavirus E2 protein onto chromatin during DNA synt

54 h and prolong survival in melanoma and human papillomavirus E7 in vivo tumor models.

55 V type 2, influenza hemagglutinin, and human papillomavirus E7 protein.

56 Several serine and threonine residues of the papillomavirus early E2 protein have been found to be ph

57 The papillomavirus genomes within PaVE have been further ann

58 Human papillomavirus genotype-specific concordance is more com

59 Human papillomavirus genotyping is important to study natural

60 tterance interaction for communicating human papillomavirus health information.

61 gue, SARS-Cov-2 (inducer of COVID-19), human papillomavirus, HIV, etc.) viruses and diagnosis of viru

62 between delta papillomavirus BPV-1 and alpha papillomavirus HPV-31 E2.

63 was utilized to quantitatively detect human papillomavirus (HPV) 16 and 18 DNAs with sensitivities o

64 Human papillomavirus (HPV) 16 displays substantial sequence va

65 ce of anal squamous abnormalities, and human papillomavirus (HPV) 16.

66 Natural variants of human papillomavirus (HPV) are classified into lineages and su

67 pithelium that are associated with the human papillomavirus (HPV) are far more readily cured with rad

68 ty and performance of the BD Onclarity human papillomavirus (HPV) assay (Onclarity) on the BD Viper L

69 The human papillomavirus (HPV) capsid comprises two viral proteins

70 Methylation of the human papillomavirus (HPV) DNA has been proposed as a novel bi

71 The human papillomavirus (HPV) E2 protein is a key regulator of vi

72 Human papillomavirus (HPV) E2 proteins are integral for the tr

73 E vaccination has been shown to induce human papillomavirus (HPV) E6-specific and E7-specific T-cell

74 The human papillomavirus (HPV) E7 oncoprotein is a primary driver

75 High-risk human papillomavirus (HPV) E7 proteins enable oncogenic transf

76 Swabs were human papillomavirus (HPV) genotyped, and the type-specific HP

77 led to reductions in the prevalence of human papillomavirus (HPV) genotypes 6, 11, 16, and 18 in wome

78 ions (STIs)-including a large panel of human papillomavirus (HPV) genotypes-and high-grade anal intra

79 We have developed a new human papillomavirus (HPV) genotyping assay for detection of 5

80 aseline pyrosequencing methylation and human papillomavirus (HPV) genotyping assays were performed on

81 resentative prevalence data on genital human papillomavirus (HPV) in males in the United States, usin

82 4, 0.75-0.95; k=5; I(2)=0%) and penile human papillomavirus (HPV) infection among HIV-infected MSM (0

83 ponses is critical for both persistent human papillomavirus (HPV) infection and associated cancer pro

84 (VM) may influence risk of persistent Human Papillomavirus (HPV) infection and cervical carcinogenes

85 cer screening results-namely high-risk human papillomavirus (HPV) infection and cytohistopathology-pr

86 ve data on the natural history of anal human papillomavirus (HPV) infection are scarce in human immun

87 Human papillomavirus (HPV) infection correlates with higher ra

88 Whether type-specific human papillomavirus (HPV) infection influences the risk of ac

89 High-risk human papillomavirus (HPV) infection is one of the first event

90 High-risk anal human papillomavirus (HPV) infection is prevalent among men li

91 The knowledge that persistent human papillomavirus (HPV) infection is the main cause of cerv

92 Persistent human papillomavirus (HPV) infection is the vital factor drivi

93 vide evidence of the harmful effect of human papillomavirus (HPV) infection on pregnancy, but observa

94 vaginal microbiota (VMB) composition, human papillomavirus (HPV) infection, and cervical intraepithe

95 Human papillomavirus (HPV) infection, and its sequelae of prec

96 fected youth for persistent anogenital human papillomavirus (HPV) infection, due to prolonged immunod

97 fected youth for persistent anogenital human papillomavirus (HPV) infection, due to prolonged immunod

98 Anal human papillomavirus (HPV) infection, most notably HPV16, the

99 In human papillomavirus (HPV) infection, the cellular protein com

100 ical abnormalities resembling those of human papillomavirus (HPV) infection.

101 Although new human papillomavirus (HPV) infections can occur at all ages, t

102 Oncogenic human papillomavirus (HPV) infections cause most cases of cerv

103 MPORTANCE The persistence of high-risk human papillomavirus (HPV) infections is the key risk factor f

104 e more likely to smoke and harbor oral human papillomavirus (HPV) infections, putting them at higher

105 uncover a novel mechanism by which the human papillomavirus (HPV) inhibits the activity of CBI in hea

106 Human papillomavirus (HPV) is a common sexually transmitted in

107 Human papillomavirus (HPV) is a necessary but insufficient cau

108 Persistent infection with high-risk human papillomavirus (HPV) is a prerequisite for the developme

109 Human papillomavirus (HPV) is one of the most common sexually

110 ant oncogenic HPV genotypes.IMPORTANCE Human papillomavirus (HPV) is the causative agent of cervical

111 Human papillomavirus (HPV) is the causative agent of cervical

112 Human papillomavirus (HPV) L1 and L2 capsid proteins self-asse

113 ion and complete the viral life cycle, human papillomavirus (HPV) needs to alter the transcriptional

114 critical cell cycle checkpoints by the human papillomavirus (HPV) oncoprotein E7 results in replicati

115 Oncoprotein E6 of high-risk human papillomavirus (HPV) plays a critical role in inducing c

116 Differences in oral human papillomavirus (HPV) prevalence and contrasts in HPV-att

117 To estimate changes in oral human papillomavirus (HPV) prevalence attributable to vaccinat

118 The human papillomavirus (HPV) rate of evolution is essential for

119 transmission of genital infection with human papillomavirus (HPV) relative to male-to-female (M-F).

120 The human papillomavirus (HPV) replication cycle is tightly linked

121 Differences in human papillomavirus (HPV) seroprevalence by sex have been obs

122 oma-associated herpesvirus (KSHV), and human papillomavirus (HPV) share the common property of persis

123 miRNAs associated with cancer type or human papillomavirus (HPV) status, suggesting their potential

124 settings, but quite low specificity of human papillomavirus (HPV) testing, particularly in women livi

125 pared it with post-treatment high-risk human papillomavirus (HPV) testing.

126 Inexpensive and easy-to-perform human papillomavirus (HPV) tests are needed for primary cervic

127 cer incidence is rapidly rising due to human papillomavirus (HPV) type 16 infection.

128 s treatment success, defined as either human papillomavirus (HPV) type-specific clearance among parti

129 tland launched routine vaccination for human papillomavirus (HPV) types 16 and 18, targeted at 12-13-

130 tive immunogenicity against nonvaccine human papillomavirus (HPV) types 31 and 45 following 2 doses o

131 ely 90% of genital warts are caused by human papillomavirus (HPV) types 6 and 11.

132 the relative carcinogenic potential of human papillomavirus (HPV) types among women infected with hum

133 Specimens were tested for 37 human papillomavirus (HPV) types and for FAM19A4 and microRNA1

134 Human papillomavirus (HPV) types differ by geographic location

135 the rate of subsequent GWs, associated human papillomavirus (HPV) types, and time to subsequent GW ev

136 We designed a universal human papillomavirus (HPV) typing assay based on target enrich

137 global efforts, we modelled potential human papillomavirus (HPV) vaccination and cervical screening

138 Efforts are being made to scale up human papillomavirus (HPV) vaccination for adolescent girls in

139 Human papillomavirus (HPV) vaccination has been associated wit

140 A reduced, 2-dose schedule of human papillomavirus (HPV) vaccination has been endorsed for p

141 In the United States, human papillomavirus (HPV) vaccination has been recommended fo

142 Cervical screening and human papillomavirus (HPV) vaccination have been implemented i

143 tan implemented a national program for human papillomavirus (HPV) vaccination in 2010 involving girls

144 ealth impact and cost-effectiveness of human papillomavirus (HPV) vaccination in girls.

145 the United States, the routine age for human papillomavirus (HPV) vaccination is 11 to 12 years, with

146 Human papillomavirus (HPV) vaccination is safe and efficacious

147 Human papillomavirus (HPV) vaccination is suboptimally used in

148 creasing evidence suggests that 1-dose human papillomavirus (HPV) vaccination may protect significant

149 Human papillomavirus (HPV) vaccination of girls with very high

150 untries have implemented a 2-dose (2D) human papillomavirus (HPV) vaccination schedule for adolescent

151 ation of immunity induced by different human papillomavirus (HPV) vaccination schedules and the immun

152 ntion coverage targets for scale-up of human papillomavirus (HPV) vaccination to 90%, twice-lifetime

153 More than 10 years have elapsed since human papillomavirus (HPV) vaccination was implemented.

154 Before 2016, human papillomavirus (HPV) vaccination was recommended in a th

155 Before 2016, human papillomavirus (HPV) vaccination was recommended on a 3-

156 demand for treatment in the context of human papillomavirus (HPV) vaccination.

157 ported across AS04-adjuvanted bivalent human papillomavirus (HPV) vaccine (2vHPV) studies, we reevalu

158 Uptake of human papillomavirus (HPV) vaccine among girls in the Dutch im

159 To understand real-world human papillomavirus (HPV) vaccine impact, continuous evaluati

160 and effectiveness of the quadrivalent human papillomavirus (HPV) vaccine in preventing high-grade ce

161 The bivalent human papillomavirus (HPV) vaccine is highly effective and ind

162 Despite an efficacious prophylactic human papillomavirus (HPV) vaccine there is still a considerab

163 oma in situ (CIN2+) during a period of human papillomavirus (HPV) vaccine uptake and changing cervica

164 Human papillomavirus (HPV) vaccine was recommended in 2006 for

165 Human papillomavirus (HPV) vaccines are indicated for anal can

166 available PM vaccine and the marketed Human Papillomavirus (HPV) vaccines are prohibitively expensiv

167 Highly effective human papillomavirus (HPV) vaccines are used in many national

168 We studied the association between human papillomavirus (HPV) viral load (VL) and HPV concordance

169 tegrations of hepatitis B virus (HBV), human papillomavirus (HPV), Epstein-Barr virus (EBV), and BK V

170 first national study in Togo to assess human papillomavirus (HPV), HIV, and other sexually transmitte

171 reasingly attributed to infection with human papillomavirus (HPV), primarily HPV-16.

172 bidities related to infection with the human papillomavirus (HPV), yet their HPV vaccine initiation r

173 lular immunotherapeutics targeting the human papillomavirus (HPV)-16 E6 and E7 proteins have achieved

174 ciency virus (HIV) are at high risk of human papillomavirus (HPV)-associated cancers.

175 herapy for the treatment of metastatic human papillomavirus (HPV)-associated epithelial cancers.

176 The survival disparity was confined to human papillomavirus (HPV)-associated oropharyngeal cancers, s

177 ) is implicated in the pathogenesis of human papillomavirus (HPV)-associated oropharyngeal squamous c

178 a sensitive and specific biomarker of human papillomavirus (HPV)-associated oropharyngeal squamous c

179 ver, the role of gammadelta T cells in human papillomavirus (HPV)-associated uterine cervical SCC, th

180 We detected human papillomavirus (HPV)-clade-specific differences in tumor

181 atural lesions, organotypic rafts, and human papillomavirus (HPV)-immortalized keratinocytes are alte

182 HIV enhances human papillomavirus (HPV)-induced carcinogenesis.

183 vels were significantly upregulated in human papillomavirus (HPV)-infected cell lines and tissues.

184 Human papillomavirus (HPV)-negative oropharyngeal squamous cel

185 of a homozygous ITK mutation with beta-human papillomavirus (HPV)-positive epidermodysplasia verrucif

186 Human papillomavirus (HPV)-positive head and neck squamous cel

187 Patients with human papillomavirus (HPV)-positive head and neck squamous cel

188 The incidence of human papillomavirus (HPV)-positive oropharyngeal cancer, a di

189 Patients with human papillomavirus (HPV)-positive oropharyngeal squamous cel

190 Compared to primary human papillomavirus (HPV)-positive tumors, many recurrent and

191 Human papillomavirus (HPV)-related biomarkers have shown good

192 his study was to determine the risk of human papillomavirus (HPV)-related carcinomas and premalignanc

193 Here we show that human papillomavirus (HPV)-specific B cell responses are detec

194 atosis is a benign condition caused by human papillomavirus (HPV).

195 e 4 and 6 (CDK4/6), rather than by the human papillomavirus (HPV).

196 y epidemic rate, largely driven by the human papillomavirus (HPV).

197 inogens or malignant transformation by human papillomavirus (HPV).

198 n largely associated with tobacco use, human papillomavirus (HPV+) oropharynx cancer has in recent ye

199 Oncogenic human papillomaviruses (HPV) are small DNA viruses that infect

200 High-risk human papillomaviruses (HPV) are the causative agents of cervi

201 Human papillomaviruses (HPV) cause over 500 000 cervical cance

202 Human papillomaviruses (HPV) replicate their genomes in differ

203 by vaccine-preventable infections with human papillomaviruses (HPV).

204 cers are associated with infections by human papillomaviruses (HPV).

205 The study accrued 59 patients (human papillomavirus [HPV] positive, n = 34; HPV negative, n =

206 bly, glycopolymers efficiently inhibit Human Papillomavirus (HPV16) infection in vitro and maintain t

207 ital LAMP on a sp-SlipChip to quantify human papillomaviruses (HPVs) 16 and 18 and tested this method

208 Human papillomaviruses (HPVs) are a significant public health

209 Antibodies against human papillomaviruses (HPVs) are biomarkers for current or pa

210 Human papillomaviruses (HPVs) are causative agents in ano-geni

211 Oncogenic human papillomaviruses (HPVs) are closely linked to major huma

212 tion of viral DNA synthesis.IMPORTANCE Human papillomaviruses (HPVs) are highly infectious pathogens

213 Infection caused by high-risk human papillomaviruses (HPVs) are implicated in the aetiology

214 Human papillomaviruses (HPVs) are the most common sexually tra

215 High-risk human papillomaviruses (HPVs) constitutively activate ataxia t

216 We report that oncogenic human papillomaviruses (HPVs) generate circRNAs, some of which

217 out the epidemiology of beta and gamma human papillomaviruses (HPVs) in oral cavities of healthy wome

218 Human papillomaviruses (HPVs) infect keratinocytes of stratifi

219 Human papillomaviruses (HPVs) infect squamous epithelia and ca

220 e E6 protein of both mucosal high-risk human papillomaviruses (HPVs) such as HPV-16, which have been

221 To replicate, the human papillomaviruses (HPVs) that cause anogenital and oropha

222 h many high-risk mucosal and cutaneous human papillomaviruses (HPVs) theoretically have the potential

223 Two common human papillomaviruses (HPVs), HPV-6 and -11, are implicated i

224 Evidence suggests that beta human papillomaviruses (HPVs), together with ultraviolet radia

225 e risk of anal cancer due to high-risk human papillomavirus (HR-HPV) is higher in women living with h

226 id-based cytology (aLBC) and high-risk human papillomavirus (HR-HPV) testing to predict histological

227 High-risk human papillomaviruses (HR-HPVs) promote cervical cancer as we

228 High-risk human papillomavirus (hrHPV) causes cervical cancer.

229 d the trend in prevalence of high-risk human papillomavirus (hrHPV) cervical infection among Rwandan

230 a role in modulating risk of high-risk human papillomavirus (hrHPV) infection.

231 idence and clearance of anal high-risk human papillomavirus (hrHPV) infections and determinants there

232 diagnostic test accuracy of high-risk human papillomavirus (hrHPV) testing of self-collected urine a

233 High-risk human papillomavirus (hrHPV) testing to triage women with mino

234 , for example, Helicobacter pylori and human papillomavirus in the cases of gastric non-cardia and ce

235 unctions, such as a potential role for human papillomavirus-induced chromosomal alterations in ovaria

236 represents a major advancement in models of papillomavirus-induced pathogenesis/carcinogenesis, and

237 This papillomavirus-induced skin cancer model opens future in

238 the action of the CCR6/CCL20 axis.IMPORTANCE Papillomaviruses infect stratified squamous epithelia, a

239 oss clinical and histopathological images of papillomavirus infected lesions.

240 high total cholesterol, hypertension, human papillomavirus infection and related pre-cancerous stage

241 experimental data implicate cutaneous human papillomavirus infection as co-factor in the development

242 widespread testing for the presence of human papillomavirus infection in patients with HNSCC.

243 high total cholesterol, hypertension, human papillomavirus infection, and related precancerous stage

244 ent L1 isoforms during the natural course of papillomavirus infection.

245 eled to recognize the signs of genital human papillomavirus infection.

246 immunoregulatory control of oncogenic human papillomavirus infection.

247 nome integration.IMPORTANCE Persistent human papillomavirus infections can cause a variety of signifi

248 The number of papillomavirus infections detected was greater among His

249 upport a working model of innate immunity to papillomaviruses involving the activation of a MyD88-dep

250 ntributes to infectious entry.IMPORTANCE The papillomavirus L2 capsid protein plays an essential role

251 ine a completely new means of regulating the papillomavirus L2 proteins, a regulation that optimizes

252 Human papillomavirus may also be associated with intrauterine

253 The papillomavirus, MmuPV1, which infects laboratory mice (M

254 is Gem, we discuss the discovery of a murine papillomavirus, Mus musculus papillomavirus 1 (MmuPV1),

255 were enrolled, patients known to have human papillomavirus-negative tumors were ineligible.

256 ly transmitted infections and to treat human papillomavirus neoplasia.

257 To investigate the effects of papillomavirus on carcinogen-driven skin cancer, we colo

258 of vaccinating girls and women against human papillomavirus on HPV infections, anogenital wart diagno

259 Infection-based models of papillomavirus pathogenesis have been complicated by the

260 rotaviruses, picobirnaviruses, parvoviruses, papillomaviruses, polyomaviruses, and a gammaherpesvirus

261 Human papillomavirus-positive oropharynx cancer incidence has

262 on emission tomography in mice bearing human papillomavirus-positive tumors, as well as influenza A v

263 Human papillomavirus prevalence and determinants of genotype-s

264 The papillomavirus (PV) E2 protein coordinates viral transcr

265 The papillomavirus (PV) E2 protein is a critical regulator o

266 ne (K111), highly conserved among almost all papillomavirus (PV) E2 proteins, is a target for P300 (E

267 gh the Y102 residue of HPV E2.IMPORTANCE The papillomavirus (PV) is a double-stranded DNA tumor virus

268 ted by phosphorylation of E2 Y138.IMPORTANCE Papillomavirus (PV) is a double-stranded DNA tumor virus

269 Papillomaviruses (PVs) are small, double-stranded DNA vi

270 es the nuclear cellular machinery.IMPORTANCE Papillomaviruses (PVs) comprise a large family of nonenv

271 The detection of known human papillomaviruses (PVs) from targeted wet-lab approaches

272 The Papillomavirus Rapid Interface for Modelling and Economi

273 ols on patient-derived xenografts from human papillomavirus-related (HPV(+)) head and neck squamous c

274 e of this approach to both prevent and treat papillomavirus-related disease.

275 Using human papillomavirus-related oropharyngeal carcinoma as a mode

276 an example, we applied our pipeline to human papillomavirus-related oropharyngeal squamous cell carci

277 ammatory skin diseases and in limiting human papillomavirus replication in human keratinocytes.

278 th the appropriate peptides, we imaged human papillomavirus-specific CD8(+) T cells by positron emiss

279 Although patients with unknown human papillomavirus status were enrolled, patients known to h

280 variable analysis adjusting for stage, human papillomavirus status, and smoking history.

281 randomly assigned (1:1), stratified by human papillomavirus status, to nivolumab (3 mg/kg intravenous

282 show that T cell immunity against commensal papillomaviruses suppresses skin cancer in immunocompete

283 Human papillomavirus transgenic mice bearing CIN lesions were

284 In human papillomavirus transgenic mice engineered to express hum

285 preventive effect of MPA was absent in human papillomavirus transgenic mice in which the expression o

286 In a human papillomavirus tumor model system, a single s.c. injecti

287 l strains of immunocompetent mice with mouse papillomavirus type 1 (MmuPV1)(5).

288 Several human papillomavirus type 16 (HPV16) oncoproteins contribute t

289 transgenic mice engineered to express human papillomavirus type 16 E6 and E7, short-term treatment w

290 (+) T cell responses against high-risk human papillomavirus type 16 E7 oncoprotein and conferred CD8-

291 ns, such as the oncogene protein E7 of human papillomavirus type 16, which contain both ordered and d

292 Human papillomavirus types were stratified as vaccine types (H

293 ite is very highly conserved across multiple papillomavirus types, indicating a highly conserved func

294 on Dialogue Ontology for patient-level human papillomavirus vaccine counseling and potentially for an

295 ted States and parts of the world, the human papillomavirus vaccine uptake is below the prescribed co

296 ced autoimmune diseases; (5) safety of human papillomavirus vaccine; (6) aluminum adjuvant-induced au

297 Human papillomavirus was significantly associated with preterm

298 ruses, human pegivirus 1, herpesviruses, and papillomaviruses were detected in RNA-seq data, but prop

299 s indicate that MmuPV1 is a new model animal papillomavirus with which to study sexually transmission

300 o suggest that eukaryotic polyomaviruses and papillomaviruses with dsDNA genomes have evolved via par